Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of sunitinib versus standard-of-care in previously treated triple-negative breast cancer
2005-003774-15Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in triple-negative breast cancer (TNBC) and breast cancer comparing Sutent arm with Standard-of-care arm (2 arms). Primary endpoint: Progression-free survival. Started Oct 2005; status: completed.
02
Drugs
sunitinib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2005-003774-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003774-15.